A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 08 May 2017
At a glance
- Drugs CDX-3379 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Pharmacodynamics
- Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals
- 07 Jun 2017 Biomarkers information updated
- 04 May 2017 Status changed from active, no longer recruiting to completed.
- 04 Apr 2017 Planned End Date changed from 1 May 2017 to 14 Apr 2017.